Universal Biosensors, Inc. (ASX: UBI) today announced positive results in a clinical study assessing the
performance of its next major point of care technology, the PT/INR strip and meter system. The system
prototype showed excellent correlation with the current market leader in the US$400m1 point of care
PT/INR market which bodes well for the next phase of its development, clinical testing and ultimately
commercialisation.
View the article
All News